In this article, we will look at the 10 Best 52-Week Low Penny Stocks to Buy Now.

On March 26, Gabelli released its Small Cap Outlook for 2025 and beyond. The firm highlighted small-cap stocks as an attractive investment opportunity, noting that the sector has been undervalued compared to large-cap stocks, especially mega-cap tech companies. This has created a wide valuation gap that has the potential to benefit long-term investors who seek diversification.

The positive outlook of Gabelli for the small caps is based on numerous factors, including current valuations, economic conditions, and key industry trends like increased mergers and acquisitions, reshoring of manufacturing, and tax or regulatory changes. The firm notes that despite inflation and interest rate pressures, this sector has shown resilience.

Moreover, from 2010 to 2017, the Russell 2000 had generally traded at higher forward P/E multiples than large caps. However, the valuation gap shifted since 2018, when the large caps gained a significant premium. More recently, in 2023, the Russell 1000 outperformed the Russell 2000 with total returns of 26.5% versus 16.9%, respectively. Large-cap growth stocks, powered by mega-cap tech and AI beneficiaries, continued to lead returns, while the small-cap value showed relative strength but did not close the overall gap. The report highlighted that the earnings growth forecasts for the Russell 2000 have remained elevated, supporting the idea that the performance gap is narrowing. Therefore, the persistent valuation discount for small caps, combined with stabilizing earnings and broadening economic growth, suggests that small caps may be poised for relative outperformance going forward.

With that, let’s take a look at the 10 best 52-week low penny stocks to buy now.

Our Methodology

To curate the list of 10 best 52-week low penny stocks to buy now, we used the Finviz stock screener, Yahoo Finance, and CNN as our sources. Using the screener, we aggregated a list of penny stocks (below $5) trading at 0% to 5% of their 52-week lows with an upside potential of at least 50%. Next, we cross-checked the stock price and 52-week ranges from Yahoo Finance and analyst upside potential from CNN. Lastly, we ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s Q1 2025 database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Best 52-Week Low Penny Stocks to Buy Now

10. Waldencast plc (NASDAQ:WALD)

Price: $1.74

52-Week Range: $1.68 – $4.74

Analyst Upside Potential: 129.89%

Number of Hedge Fund Holders: 10

Waldencast plc (NASDAQ:WALD) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 23, Waldencast plc (NASDAQ:WALD) announced the acquisition of Novaestiq Corp. and the US rights to the Saypha line of hyaluronic acid injectable gels.

This strategic acquisition expands Obagi Medical’s offerings beyond skincare into the dermal filler market in the US. Management noted that the skincare market is expected to reach $2.2 billion by 2029, while the dermal filler market is projected at $2 billion. The acquisition doubles the company’s addressable market.

Waldencast plc (NASDAQ:WALD) will now offer injectable HA gels named Saypha to integrate medical-grade skincare with aesthetic treatments for better, longer-lasting results and higher patient satisfaction.

Waldencast plc (NASDAQ:WALD) is an international beauty and wellness company that develops purpose-driven brands.

9. MaxCyte, Inc. (NASDAQ:MXCT)

Price: $2.06

52-Week Range: $1.965 – $5.2

Analyst Upside Potential: 239.81%

Number of Hedge Fund Holders: 12

MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

As part of this agreement, Adicet gets non-exclusive rights to use MaxCyte, Inc.’s (NASDAQ:MXCT) Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. The company has developed a unique process to activate and grow specific gamma delta T cells, enabling large-scale production of off-the-shelf cell therapies ready for clinical use. The approach combines non-viral gene editing with an efficient expansion system to create powerful therapies aimed at treating various cancers and autoimmune conditions. MaxCyte, Inc.’s (NASDAQ:MXCT) ExPERT technology offers advanced electroporation tools that ensure high gene transfer efficiency, cell viability, and scalability.

MaxCyte, Inc. (NASDAQ:MXCT) develops advanced cell-engineering technologies to help biotech and pharmaceutical companies create next-generation cell therapies.